The modified Geller-Seifter test in rats was insensitive to GABA B receptor positive modulation or blockade, or 5-HT 1A receptor activation

Behavioural Brain Research

Volumn 208, Issue 1, 2010, Pages 258-264

  Paterson, Neil E ^a   Hanania, Taleen ^a  

^a PSYCHOGENICS INC   (United States)

Author keywords

8 OH DPAT; Alprazolam; CGP46381; GABA B receptor positive modulator; Geller Seifter; GS39783; MPEP; Predictive validity

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 4 AMINOBUTYRIC ACID B RECEPTOR; ALPRAZOLAM; ANXIOLYTIC AGENT; CGP 46381; CHLORDIAZEPOXIDE; DIAZEPAM; HALOPERIDOL; N,N' DICYCLOPENTYL 2 METHYLTHIO 5 NITRO 4,6 PYRIMIDINEDIAMINE; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID A RECEPTOR; 6 METHYL 2 (PHENYLETHYNYL)PYRIDINE; 6-METHYL-2-(PHENYLETHYNYL)PYRIDINE; AMINO ACID RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; GABAERGIC RECEPTOR AFFECTING AGENT; PYRIDINE DERIVATIVE; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; MALE; MENTAL TASK; MENTAL TEST; MODIFIED GELLER SEITER TEST; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; TASK PERFORMANCE; TRANQUILIZING ACTIVITY; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; CONFLICT; DISEASE MODEL; DOSE RESPONSE; ELECTRIC SHOCK; INSTRUMENTAL CONDITIONING; METABOLISM; METHODOLOGY; PHYSIOLOGY; REINFORCEMENT; REPRODUCIBILITY; SPRAGUE DAWLEY RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; CONFLICT (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; EXCITATORY AMINO ACID ANTAGONISTS; GABA AGENTS; HALOPERIDOL; MALE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, GABA-A; REINFORCEMENT SCHEDULE; REPRODUCIBILITY OF RESULTS; SEROTONIN AGONISTS;

EID: 77951894045     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.12.006     Document Type: Article

References (41)

1. Abrams J.K., Johnson P.L., Hollis J.H., Lowry C.A. Anatomic and functional topography of the dorsal raphe nucleus. Ann N Y Acad Sci 2004, 1018:46-57.
2. Ballard T.M., Woolley M.L., Prinssen E., Huwyler J., Porter R., Spooren W. The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. Psychopharmacology 2005, 179(1):218-229.
3. Busse C.S., Brodkin J., Tattersall D., Anderson J.J., Warren N., Tehrani L., et al. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 2004, 29(11):1971-1979.
4. Chessick C.A., Allen M.H., Thase M., Batista Miralha da Cunha A.B., Kapczinski F.F., de Lima M.S., et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006, 3. [CD006115].
5. Collinson N., Dawson G.R. On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635. Psychopharmacology 1997, 132(1):35-43.
6. Cryan J.F., Kaupmann K. Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci 2005, 26(1):36-43.
7. Cryan J.F., Kelly P.H., Chaperon F., Gentsch C., Mombereau C., Lingenhoehl K., et al. Behavioural characterization of the novel GABAB receptor positive modulator GS39783 (N,N0-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side-effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther 2004, 310:952-963.
8. Davidson J.R. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry 2009, 70(Suppl. 2):25-31.
9. Geller I., Kulak J.T., Seifter J. The effects of chlordiazepoxide and chlorpromazine on a punishment discrimination. Psychopharmacologia 1962, 3:374-385.
10. Harsing L.R. The pharmacology of the neurochemical transmission in the midbrain raphe nuclei of the rat. Curr Neuropharmacol 2006, 4:313-339.
11. Jacobson L.H., Cryan J.F. Evaluation of the anxiolytic-like profile of the GABAB receptor positive modulator CGP7930 in rodents. Neuropharmacology 2008, 54(5):854-862.
12. Ketelaars C.E., Bollen E.L., Rigter H., Bruinvels J. GABA-B receptor activation and conflict behaviour. Life Sci 1998, 42:933-942.
13. Kilts C.D., Commissaris R.L., Rech R.H. Comparison of anti-conflict drug effects in three experimental animal models of anxiety. Psychopharmacology 1981, 74(3):290-296.
14. King C.M., Gommans J., Joordens R.J., Hijzen T.H., Maes R.A., Olivier B. Effects of 5-HT1A receptor ligands in a modified Geller-Seifter conflict model in the rat. Eur J Pharmacol 1997, 325(2-3):121-128.
15. Kuribara H., Asahi T. Assessment of the anxiolytic and amnesic effects of three benzodiazepines, diazepam, alprazolam and triazolam, by conflict and non-matching to sample tests in mice. Nihon Shinkei Seishin Yakurigaku Zasshi 1997, 17(1):1-6.
16. Macey D.J., Froestl W., Koob G.F., Markou A. Both GABA(B) receptor agonist and antagonists decreased brain stimulation reward in the rat. Neuropharmacology 2001, 40(5):676-685.
17. Mannoury la Cour C., Hanoun N., Melfort M., Hen R., Lesch K.P., Hamon M., et al. GABA(B) receptors in 5-HT transporter- and 5-HT1A receptor-knock-out mice: further evidence of a transduction pathway shared with 5-HT1A receptors. J Neurochem 2004, 89(4):886-896.
18. Martin J.R., Ballard T.M., Higgins G.A. Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol Biochem Behav 2002, 71(4):615-625.
19. Mombereau C., Kaupmann K., Froestl W., Sansig G., van der Putten H., Cryan J.F. Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 2004, 29(6):1050-1062.
20. Mombereau C., Kaupmann K., van der Putten H., Cryan J.F. Altered response to benzodiazepine anxiolytics in mice lacking GABA B(1) receptors. Eur J Pharmacol 2004, 497(1):119-120.
21. Mombereau C., Lhuillier L., Kaupmann K., Cryan J.F. GABAB receptor-positive modulation-induced blockade of the rewarding properties of nicotine is associated with a reduction in nucleus accumbens DeltaFosB accumulation. J Pharmacol Exp Ther 2007, 321(1):172-177.
22. Moore N.A., Tye N.C., Axton M.S., Risius F.C. The behavioral pharmacology of olanzapine, a novel " atypical" antipsychotic agent. J Pharmacol Exp Ther 1992, 262(2):545-551.
23. Moser P.C., Tricklebank M.D., Middlemiss D.N., Mir A.K., Hibert M.F., Fozard J.R. Characterization of MDL 73005EF as a 5-HT1A selective ligand and its effects in animal models of anxiety: comparison with buspirone, 8-OH-DPAT and diazepam. Br J Pharmacol 1990, 99(2):343-349.
24. National Institutes of Health Guide for the care and use of laboratory animals 1996, National Academy Press, Washington, DC.
25. Olpe H.R., Steinmann M.W., Ferrat T., Pozza M.F., Greiner K., Brugger F., et al. The actions of orally active GABAB receptor antagonists on GABAergic transmission in vivo and in vitro. Eur J Pharmacol 1993, 233(2-3):179-186.
26. Partyka A., Kłodzińska A., Szewczyk B., Wierońska J.M., Chojnacka-Wójcik E., Librowski T., et al. Effects of GABAB receptor ligands in rodent tests of anxiety-like behavior. Pharmacol Rep 2007, 59(6):757-762.
27. Paterson N.E., Froestl W., Markou A. The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology 2004, 172(2):179-186.
28. Paterson N.E., Vlachou S., Guery S., Kaupmann K., Froestl W., Markou A. Positive modulation of GABA(B) receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats. J Pharmacol Exp Ther 2008, 326(1):306-314.
29. Porter R.H., Jaeschke G., Spooren W., Ballard T.M., Büttelmann B., Kolczewski S., et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 2005, 315(2):711-721.
30. Sanger D.J. Increased rates of punished responding produced by buspirone-like compounds in rats. J Pharmacol Exp Ther 1992, 261(2):513-517.
31. Schreiber R., De Vry J. Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT ipsapirone and buspirone in the rat. Eur J Pharmacol 1993, 249(3):341-351.
32. Shephard R.A., Wedlock P., Wilson N.E. Direct evidence for mediation of an anticonflict effect of baclofen by GABAb receptors. Pharmacol Biochem Behav 1992, 41:651-653.
33. Shimizu H., Kumasaka Y., Tanaka H., Hirose A., Nakamura M. Anticonflict action of tandospirone in a modified Geller-Seifter conflict test in rats. Jpn J Pharmacol 1992, 58(3):283-289.
34. Slattery D.A., Desrayaud S., Cryan J.F. GABAB receptor antagonist-mediated antidepressant-like behavior is serotonin-dependent. J Pharmacol Exp Ther 2005, 312(1):290-296.
35. Slattery D.A., Markou A., Froestl W., Cryan J.F. The GABAB receptor-positive modulator GS39783 and the GABAB receptor agonist baclofen attenuate the reward-facilitating effects of cocaine: intracranial self-stimulation studies in the rat. Neuropsychopharmacology 2005, 30(11):2065-2072.
36. Smith M.A., Yancey D.L., Morgan D., Liu Y., Froestl W., Roberts D.C. Effects of positive allosteric modulators of the GABAB receptor on cocaine self-administration in rats. Psychopharmacology 2004, 173(1-2):105-111.
37. Urwyler S., Mosbacher J., Lingenhoehl K., Heid J., Hofstetter K., Froestl W., et al. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 2001, 60(5):963-971.
38. Urwyler S., Pozza M.F., Lingenhoehl K., Mosbacher J., Lampert C., Froestl W., et al. N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acid B receptor function. J Pharmacol Exp Ther 2003, 307(1):322-330.
39. Vogel R.A., Frye G.D., Wilson J.H., Kuhn C.M., Koepke K.M., Mailman R.B., et al. Attenuation of the effects of punishment by ethanol: comparisons with chlordiazepoxide. Psychopharmacology 1980, 71(2):123-129.
40. Wiley J.L., Compton A.D., Porter J.H. Effects of four antipsychotics on punished responding in rats. Pharmacol Biochem Behav 1993, 45(2):263-267.
41. Wood M.D., Reavill C., Trail B., Wilson A., Stean T., Kennett G.A., et al. SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology 2001, 41(2):186-199.